Grace Therapeutics Inc's ROA from the first quarter of 2026 to the first quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Grace Therapeutics Inc's ROA in the first quarter of 2026?
Grace Therapeutics Inc recorded a cumulative net loss of $-20 million during 12 months ending in the first quarter of 2026, resulting in a negative return on assets (ROA) of -30.35%.

However, within the Healthcare sector 534 other companies had a higher return on assets. While return on assets, the total ranking has deteriorated compared to the fourth quarter of 2026 from 3600 to 4169.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) I. Quarter	(Mar 31 2026) IV. Quarter	(Dec 31 2025) III. Quarter	(Sep 30 2025) II. Quarter	(Jun 30 2025) I. Quarter
Y / Y Total Assets Change	-28.27 %	7.46 %	32.42 %	31.01 %	30.71 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-20	-8	-6	-8	-10
Return On Assets (TTM)	-30.35 %	-10.89 %	-8.52 %	-11.89 %	-16.68 %
GRCE's Total Ranking	# 4169	# 3600	# 3601	# 3708	# 5011
Total Assets (TTM) in million	50	78	72	67	70
Seq. Total Assets Change	-35.48 %	7.46 %	8.48 %	-4.63 %	-3.34 %
Seq. Net Income Change	-	-	-	-	-

GRCE's 5 Years Annual ROA >> Back to GRCE Management Effectiveness >> Compare GRCE ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 218
Sector	# 535
Overall	# 4426

Return On Assets Statistics
High	Average	Low
12.97 %	-22.3 %	-65.99 %
(Dec 31 2020)		(Mar 31 2021)

Financial Statements
Grace Therapeutics Inc's Assets	$ 50 million	GRCE's Balance sheet
Grace Therapeutics Inc's Income	$ -16 million	Quarterly GRCE's Income Statement
GRCE's Income by Division		See GRCE's Income by Division

Annual Return On Assets	(Mar 31 2026) FY 2026	(Mar 31 2025) FY 2025	(Mar 31 2024) FY 2024	(Mar 31 2023) FY 2023	(Mar 31 2022) FY 2022
Y / Y Total Assets Change	7.46 %	32.42 %	-21.1 %	-60.52 %	122.68 %
Total Assets in million	78	72	55	69	175
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-8	-10	-13	-42	-10
Annual Return On Assets	-10.04 %	-13.25 %	-23.57 %	-61.38 %	-5.61 %

GRCE's 5 Years Annual ROA >> Back to GRCE Management Effectiveness >> Compare GRCE ROA to its Competitors

More Return On Assets Ratios
GRCE's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
GRCE's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for GRCE's Competitors
Subscribers only: Roa for Grace Therapeutics Inc's Suppliers
Subscribers only: Return On Assets for GRCE's Customers

You may also want to know
GRCE's Roi	GRCE's Inventory Turnover Ratio	GRCE's Growth Rates	GRCE's Dividend Comparisons
	GRCE's Profitability Ratios	GRCE's Asset Turnover Ratio	GRCE's Dividend Growth
GRCE's Roe	GRCE's Valuation Ratios	GRCE's Financial Strength Ratios	GRCE's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-03T11:49:29+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.